Subject(s)
Prostatic Neoplasms , Male , Humans , Prostatic Neoplasms/drug therapy , Androstenes/therapeutic use , HormonesABSTRACT
La terapia de privación androgénica (TPA) es el pilar del tratamiento del cáncer de próstata hormono-sensible metastásico (CPHSm). La adición de docetaxel o de nuevas terapias hormonales (abiraterona, apalutamida o enzalutamida) mejora la supervivencia global (SG) y es en la actualidad el estándar de tratamiento. Sin embargo, la decisión sobre el régimen específico que acompañe a la TPA debe ser discutida con el paciente teniendo en cuenta factores como las posibles toxicidades asociadas, la duración del tratamiento, las comorbilidades o sus preferencias, pues no hay evidencia suficiente para recomendar un régimen sobre otro en la mayoría de los casos. En este trabajo se resume la evidencia sobre el manejo del CPHSm y se aportan recomendaciones consensuadas sobre el tratamiento óptimo para añadir a la TPA en pacientes con CPHSm con especial atención al perfil clínico del paciente (AU)
Androgen deprivation therapy (ADT) is the mainstay treatment for metastatic hormone-sensitive prostate cancer (mHSPC). The addition of docetaxel or new hormone therapies (abiraterone, apalutamide, or enzalutamide) improves overall survival and is currently the standard of care. However, the decision on the specific regimen to accompany ADT should be discussed with the patient, considering factors such as possible associated toxicities, duration of treatment, comorbidities, patient preferences, as there is no sufficient evidence to recommend one regimen over the other in most cases. This paper summarizes the evidence on the management of mHSPC and provides consensus recommendations on the optimal treatment in combination with ADT in mHSPC patients, with special attention to the patient's clinical profile (AU)
Subject(s)
Humans , Male , Interdisciplinary Research , Prostatic Neoplasms/drug therapy , Androgen Antagonists/therapeutic use , Patient Safety , Consensus Development Conferences as Topic , Neoplasm Metastasis , Decision MakingABSTRACT
Androgen deprivation therapy (ADT) is the mainstay treatment for metastatic hormone-sensitive prostate cancer (mHSPC). The addition of docetaxel or new hormone therapies (abiraterone, apalutamide, or enzalutamide) improves overall survival and is currently the standard of care. However, the decision on the specific regimen to accompany ADT should be discussed with the patient, considering factors such as possible associated toxicities, duration of treatment, comorbidities, patient preferences, as there is no sufficient evidence to recommend one regimen over the other in most cases. This paper summarizes the evidence on the management of mHSPC and provides consensus recommendations on the optimal treatment in combination with ADT in mHSPC patients, with special attention to the patient's clinical profile.
Subject(s)
Prostatic Neoplasms , Male , Humans , Prostatic Neoplasms/pathology , Androgen Antagonists/therapeutic use , Treatment Outcome , Docetaxel/therapeutic use , Hormones/therapeutic useABSTRACT
Prostate epithelial and stromal cells develop paracrine interactions, which may be responsible for the occurrence and progression of prostate pathologies. Strikingly, stromal cells exhibit pleiotropic effects on epithelial cell growth, ranging from stimulation to inhibition. Steroid hormone receptors are considered ligand-activated transcriptional factors. Moreover, it has been suggested that the human androgen receptor can also be activated in the absence of surrounding ligands such as growth factors and cytokines. Strong evidence suggests that cytokines may play an important role in ligand-independent activation of androgen receptor in prostate cancer cells. In our view, one of the most striking finding in the prostate cancer development process is the relationship between carcinogenesis and secretion of cytokines.
Subject(s)
Cytokines/physiology , Endocrine System/physiology , Prostatic Neoplasms/metabolism , Signal Transduction/physiology , Androgens/metabolism , Animals , Humans , Male , Receptors, Androgen/metabolismABSTRACT
Locally advanced gastric adenocarcinoma has a poor outcome. Neoadjuvant treatment is being tested in locally advanced non-resectable tumours and in those resectable tumours with a high risk of recurrence. Efforts to identify prognostic factors and more active and less toxic preoperative regimens are being searched for. We report the case of a patient achieving a complete histopathological complete response following docetaxel- based neoadjuvant chemotherapy.
Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Agents/therapeutic use , Stomach Neoplasms/drug therapy , Taxoids/therapeutic use , Adult , Chemotherapy, Adjuvant , Disease Progression , Docetaxel , Humans , Male , Neoadjuvant TherapyABSTRACT
Locally advanced gastric adenocarcinoma has a poor outcome. Neoadjuvant treatment is being tested in locally advanced non-resectable tumours and in those resectable tumours with a high risk of recurrence. Efforts to identify prognostic factors and more active and less toxic preoperative regimens are being searched for. We report the case of a patient achieving a complete histopathological complete response following docetaxel- based neoadjuvant chemotherapy (AU)
No disponible
Subject(s)
Humans , Male , Adult , Adenocarcinoma/drug therapy , Antineoplastic Agents/therapeutic use , Stomach Neoplasms/drug therapy , Taxoids/therapeutic use , Chemotherapy, Adjuvant/methods , Chemotherapy, AdjuvantSubject(s)
Autoimmunity , Chemotherapy, Adjuvant , Interferon-alpha/adverse effects , Melanoma/drug therapy , Autoantibodies/blood , Autoimmune Diseases/chemically induced , Clinical Trials, Phase III as Topic/statistics & numerical data , Dose-Response Relationship, Drug , Follow-Up Studies , Humans , Immune System/drug effects , Interferon-alpha/administration & dosage , Interferon-alpha/pharmacology , Interferon-alpha/therapeutic use , Melanoma/immunology , Melanoma/mortality , Prognosis , Purpura, Thrombocytopenic, Idiopathic/chemically induced , Randomized Controlled Trials as Topic , Survival Analysis , Thyrotoxicosis/chemically induced , Vitiligo/chemically inducedSubject(s)
Humans , Autoimmunity , Chemotherapy, Adjuvant/methods , Chemotherapy, Adjuvant , Clinical Trials, Phase III as Topic/statistics & numerical data , Interferon-alpha/adverse effects , Melanoma/drug therapy , Purpura, Thrombocytopenic, Idiopathic/chemically induced , Purpura, Thrombocytopenic, Idiopathic/complications , Randomized Controlled Trials as Topic , Dose-Response Relationship, Drug , Autoantibodies/blood , Follow-Up Studies , Immune System , Interferon-alpha/administration & dosage , Interferon-alpha/pharmacology , Melanoma/immunology , Melanoma/mortality , Thyrotoxicosis/chemically induced , Vitiligo/chemically inducedABSTRACT
Cardiac metastases are more frequent than primary heart neoplasias. Nearly any malignant tumour may metastasize to the heart, but the most common are carcinomas rather than sarcomas. We report the case of a patient who presented with heart metastasis 6 years after resection of an uterine leiomyosarcoma. The patient died thirty months after surgical resection without evidence of cardiac recurrence. Although cardiac metastases from uterine leiomyosarcoma are exceptional, they should be suspected in the presence of suggestive symptoms, since they can be associated with long survival after surgical treatment.
Subject(s)
Heart Neoplasms/secondary , Leiomyosarcoma/secondary , Uterine Neoplasms/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Combined Modality Therapy , Dacarbazine/administration & dosage , Dacarbazine/analogs & derivatives , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Diagnostic Errors , Docetaxel , Doxorubicin/administration & dosage , Fatal Outcome , Female , Heart Neoplasms/surgery , Humans , Hysterectomy , Ifosfamide/administration & dosage , Kidney Neoplasms/drug therapy , Kidney Neoplasms/secondary , Kidney Neoplasms/surgery , Leiomyoma/diagnosis , Leiomyosarcoma/diagnosis , Leiomyosarcoma/drug therapy , Leiomyosarcoma/surgery , Lung Neoplasms/secondary , Lung Neoplasms/surgery , Middle Aged , Ovariectomy , Taxoids/administration & dosage , Temozolomide , Thoracic Surgery, Video-Assisted , Uterine Neoplasms/diagnosis , Uterine Neoplasms/surgery , GemcitabineSubject(s)
Antineoplastic Agents/adverse effects , Interferon-alpha/adverse effects , Lung Diseases, Interstitial/diagnosis , Melanoma/drug therapy , Skin Neoplasms/drug therapy , Aged , Aged, 80 and over , Diabetes Mellitus, Type 2 , Diagnosis, Differential , Female , Humans , Interferon alpha-2 , Lung Diseases, Interstitial/chemically induced , Lung Diseases, Interstitial/diagnostic imaging , Lung Diseases, Interstitial/pathology , Parkinson Disease , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/diagnosis , Pulmonary Fibrosis/diagnostic imaging , Pulmonary Fibrosis/pathology , Recombinant Proteins , Tomography, X-Ray Computed , Tuberculosis, PulmonarySubject(s)
Astrocytoma/diagnosis , Cerebellar Neoplasms/diagnosis , Aged , Aged, 80 and over , Humans , Male , Tomography, X-Ray ComputedABSTRACT
No disponible